V
Valina L. Dawson
Researcher at Johns Hopkins University School of Medicine
Publications - 477
Citations - 88024
Valina L. Dawson is an academic researcher from Johns Hopkins University School of Medicine. The author has contributed to research in topics: Neurodegeneration & Parkin. The author has an hindex of 136, co-authored 451 publications receiving 76986 citations. Previous affiliations of Valina L. Dawson include University of Baltimore & Hospital of the University of Pennsylvania.
Papers
More filters
Journal ArticleDOI
Of Flies and Mice
TL;DR: Two recent papers report the first animal models of PD in flies and mice, fueling optimism that there will be rapid further progress in working out the pathogenesis of this disease and in designing more effective treatments.
Journal ArticleDOI
What have genetically engineered mice taught us about ischemic injury
TL;DR: Genetically engineered mice have been valuable tools to probe putative mechanisms of neuronal death and uncover potential strategies that might render neurons resistant to ischemic injury.
Journal ArticleDOI
PAAN/MIF nuclease inhibition prevents neurodegeneration in Parkinson’s disease
Hyejin Park,T. I. Kam,Hanjing Peng,Shih Ching Chou,Amir A. Mehrabani-Tabari,Jae Jin Song,Xiling Yin,Senthilkumar S. Karuppagounder,George K.E. Umanah,Akanksha Rao,Yu Ree Choi,Akanksha Saurabh Aggarwal,Sohyun Laura Chang,Hyunhee Kim,Jiyoung Byun,Jun Li,Ted M. Dawson,Valina L. Dawson +17 more
TL;DR: It is shown that neurodegeneration induced by pathologic α-synuclein (α-syn) occurs via PAAN/MIF nuclease activity and could have broad relevance in human pathologies where parthanatos plays a role in the development of cell death inhibitors targeting the druggable PAAN/.
Journal ArticleDOI
A Lysosomal Lair for a Pathogenic Protein Pair
Ted M. Dawson,Valina L. Dawson +1 more
TL;DR: A reciprocal connection between loss of GBA activity and the accumulation of α-synuclein in lysosomes that establishes a bidirectional positive feedback loop with pathogenic consequences is reported.
Patent
Transcriptional repression leading to parkinson's disease
TL;DR: Parkin Interacting Substrate, PARIS (ZNF746) is identified in this article, which provides a molecular mechanism for neurodegeneration due to parkin inactivation.